The CCL14 antibody is a research tool targeting CCL14 (C-C motif chemokine ligand 14), a small cytokine belonging to the CC chemokine family. CCL14. also known as HCC-1. is encoded by the *SCYA14* gene and is constitutively expressed in various tissues, including blood, bone marrow, and organs like the liver and kidneys. It functions as a chemoattractant for immune cells, including monocytes, lymphocytes, and eosinophils, by binding to chemokine receptors CCR1. CCR3. and CCR5. CCL14 exists in multiple isoforms due to proteolytic processing, with its active form (CCL14(1-74)) exhibiting enhanced biological activity.
Research highlights CCL14's dual role in immune regulation and disease pathogenesis. While it contributes to homeostasis under normal conditions, dysregulated CCL14 expression is linked to chronic inflammation, fibrosis, and tumor progression. Elevated CCL14 levels have been observed in cancers (e.g., breast, colorectal) and fibrotic disorders, where it may promote angiogenesis, immune evasion, or tissue remodeling.
CCL14 antibodies are primarily used to detect and quantify CCL14 in biological samples, study its spatial distribution in tissues, and investigate its interaction with receptors. Neutralizing antibodies are explored for therapeutic potential in blocking CCL14-mediated signaling pathways. However, challenges remain in understanding its context-dependent functions and optimizing antibody specificity across isoforms. Ongoing studies aim to clarify CCL14's mechanistic roles and validate its utility as a diagnostic marker or therapeutic target in inflammatory and neoplastic diseases.